A differentiated clinical dataset can create a reinforcing relationship between testing and high-value research products. Q2 revenue grew 22%, with data licensing up 36% and oncology testing volume up 31%. The debate is whether that growth becomes durable cash earnings after laboratory costs, compensation, acquisitions and financing. AI branding should not obscure reimbursement and healthcare-service economics.

What the Market May Be Mispricing

Debate	Research judgment
Diagnostic reimbursement and organic volume	A differentiated clinical dataset can create a reinforcing relationship between testing and high-value research products.
Data licensing durability and legal rights	Test reimbursement, collection rates, laboratory contribution, repeat ordering and licensing renewals drive returns.
Acquisition integration, cash burn and dilution	Q2 revenue was $382.5 million and adjusted EBITDA $8 million.

Tempus combines molecular diagnostics with clinical data, AI tools and data licensing for physicians and life-science companies. Testing creates clinical and molecular information that can support research and software products, subject to consent, privacy and data rights. Diagnostics and licensing have different margins, reimbursement and cash cycles. Acquisitions, including broader hereditary and residual-disease capabilities, expand scale while complicating organic comparisons.

Business Takeaway

Tempus combines molecular diagnostics with clinical data, AI tools and data licensing for physicians and life-science companies. Test reimbursement, collection rates, laboratory contribution, repeat ordering and licensing renewals drive returns.

Precision medicine and residual-disease testing offer substantial opportunities, but clinical utility, reimbursement and physician adoption determine the reachable market. Established diagnostics companies and private clinical-data platforms compete. Large disease populations are not immediately monetizable test volumes.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Foundation Medicine — Roche	Direct: oncology molecular profiling and related clinical data	Product scope; no matched operating-scale series	Competes for specified tests and data contracts	Customer choice in the stated segment only
Guardant Health (GH)	Direct segment: liquid biopsy and oncology testing	Product scope; no matched operating-scale series	Compare assay, clinical use and reimbursement	Customer choice in the stated segment only
Natera (NTRA)	Direct segment: residual-disease/oncology monitoring	Product scope; no matched operating-scale series	Competes in overlapping oncology assays	Customer choice in the stated segment only

Industry Takeaway

Large disease populations are not immediately monetizable test volumes. The base case requires evidence of profitable adoption within that market.

Competitive Landscape

Compare a specific assay, clinical use or data product. Molecular testing companies are not interchangeable across screening, therapy selection and residual-disease monitoring.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Foundation Medicine — Roche	No consistent comparable series	Direct: oncology molecular profiling and related clinical data	Established genomic-testing and pharmaceutical relationships	Different data breadth and software/licensing mix	Competes for specified tests and data contracts
Guardant Health (GH)	No consistent comparable series	Direct segment: liquid biopsy and oncology testing	Blood-based oncology testing capabilities	Not every test or patient indication overlaps	Compare assay, clinical use and reimbursement
Natera (NTRA)	No consistent comparable series	Direct segment: residual-disease/oncology monitoring	Established molecular monitoring workflows	Other reproductive/organ-health products are outside this comparison	Competes in overlapping oncology assays

Moat Assessment

Integrated clinical and molecular data, physician relationships and workflow embedding create potential advantages. The moat remains partly dependent on acquisitions, data access and demonstrable customer outcomes.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Integrated clinical and molecular data, physician relationships and workflow embedding create potential advantages. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2024	693.4	30.38%	54.96%	-99.66%	-211.17	-30.45%	534.14	120	448.26	468.09
FY2025	1,272	83.41%	62.74%	-19.44%	-239.14	-18.80%	124.75	174	755	1,327
Q1 FY2026	$348.116	N/D	N/D	-24.3%	−$81.479 (derived: CFO - capex)	-23.4%	$52.706	0.179	$521.17	N/D
Q2 FY2026	$382.486	N/D	N/D	-19.8%	−$13.65 (derived: current YTD - prior YTD)	-3.6%	$54.121 (derived: current YTD - prior YTD)	0.182	$599.614	N/D
H1 FY2026	$730.602	N/D	N/D	-22.0%	−$95.129 (derived: CFO - capex)	-13.0%	$106.827	0.179	$599.614	N/D
Q3 FY2026	$411.537	N/D	N/D	-13.8%	−$0.122 (derived: current YTD - prior YTD)	-0.0%	$48.074 (derived: current YTD - prior YTD)	0.181	$590.479	N/D
9M FY2026	$1,142.139	N/D	N/D	-19.0%	−$95.251 (derived: CFO - capex)	-8.3%	$154.901	0.18	$590.479	N/D

Financial Takeaways

Q2 revenue was $382.5 million and adjusted EBITDA $8 million. TTM FCF remained negative $263 million, with SBC $186 million and substantial debt or convertible financing. Positive quarterly net income can include items that do not establish sustainable cash profitability. The model includes financing costs and dilution.

Financial direction: Mixed — assess the reported trend alongside dilution and the balance sheet.

Current Valuation

Metric	Value
Price Snapshot	$77.80 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$12.04B
Enterprise Value	$12.67B
Trailing P/E	n/a
Provider forward P/E	n/a
EV / Sales	8.85

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
TEM — Tempus AI, Inc.	Subject company	Public	n/a	8.85	diagnostics and clinical data; 3Y revenue-growth estimate 23.04%; operating margin -19.69%
Foundation Medicine	Direct operating competitor / substitute	Operating business of listed Roche	N/A	N/A	direct oncology testing and clinical-data competition; no compatible standalone public multiple used
NTRA — Natera	Direct selected oncology/MRD assays; other testing segments differ	Public	n/a	21.29	genetic testing and oncology monitoring; 3Y revenue-growth estimate 22.84%; operating margin -10.54%
GH — Guardant Health	Direct selected oncology/liquid-biopsy assays	Public	n/a	18.99	oncology testing and liquid biopsy; 3Y revenue-growth estimate 36.25%; operating margin -39.64%
Foundation Medicine — Roche	Direct: oncology molecular profiling and related clinical data	Operating product / listed parent	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes for specified tests and data contracts

Comparable takeaway: Compare a specific assay, clinical use or data product. Molecular testing companies are not interchangeable across screening, therapy selection and residual-disease monitoring. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR 15%; sustainable 2029 EPS $0.30 after compensation; 20× P/E; 18% discount rate; Reimbursement and financing pressure leave 2029 economic EPS at $0.30.	$3.65	30%	Execution, financing or competitive setbacks remain credible	-95.3%
Base	3Y revenue CAGR 30%; sustainable 2029 EPS $1.70 after compensation; 32× P/E; 18% discount rate; Diagnostics and data scale successfully, producing $1.70 of 2029 economic EPS.	$33.11	50%	Most likely operating trajectory, requiring measurable progress	-57.4%
Bull	3Y revenue CAGR 42%; sustainable 2029 EPS $3.50 after compensation; 40× P/E; 18% discount rate; Strong clinical adoption and high-margin data demand produce $3.50 of 2029 economic EPS.	$85.21	20%	Successful product conversion and operating leverage; not assured	+9.5%
Probability-Weighted	Sum of each scenario value × its probability	$34.69	100%	Judgmental scenario probabilities	-55.4%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: Diagnostic reimbursement and organic volume; Data licensing durability and legal rights; Acquisition integration, cash burn and dilution. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 28/100 / High. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Avoid at $66.75. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Management has built a differentiated platform but pursued an ambitious acquisition strategy. Governance, related-party exposure and the price paid for expansion deserve scrutiny. Monitor organic growth, reimbursement quality, cash burn and the common-share implications of convertibles and M&A.

Management Takeaway

Monitor organic growth, reimbursement quality, cash burn and the common-share implications of convertibles and M&A.

Analyzed call: Q2 2026, complete material Q&A · Research snapshot: 2026-10-21

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Kallum Titchmarsh / Morgan Stanley	How does reimbursement timing affect assumptions for Personalis?	Management said reimbursement timing changes partner economics.	Confirm that this opportunity converts into profitable recurring demand.
Brad Bowers / Mizuho	How do the AstraZeneca contracts affect 2027 visibility?	Management said a large customer commitment supports 2027.	Confirm that this opportunity converts into profitable recurring demand.
Kyle Mikson / Canaccord	What is the reimbursement outlook for liquid-biopsy pricing?	Management said reimbursement upside exceeds prior assumptions.	Stress monetization if competition or mix reduces economic yield.
Matt Shea / Needham	What supports data-product demand?	Management said the pipeline and customer stickiness are improving.	Confirm that this opportunity converts into profitable recurring demand.
Mark Massaro / BTIG	How are Medicare reimbursement and test economics balanced against volume growth?	Management said profitable growth takes priority over uneconomic volume.	Confirm that this opportunity converts into profitable recurring demand.
Ricki Levitus / Guggenheim	How is GenomeNext's initial ramp progressing?	Management said the first month was ahead of expectations.	Confirm that this opportunity converts into profitable recurring demand.
Brendan Smith / TD Cowen	How should investors interpret the timing of data revenue?	Management said embedded partnerships differ from one-off file sales.	Treat the stated timetable as conditional on demonstrated execution.
Robert Bamberger / Baird	How does algorithm attachment affect testing adoption?	Management said attachment supports clinical adoption and test growth.	Confirm that this opportunity converts into profitable recurring demand.

Analyst-Q&A Takeaway

Reimbursement and data partnerships improve the opportunity, but prices, revenue timing and Personalis economics remain sensitive. Profitable test volume and cash conversion matter more than assay growth alone.

Source	Type	Date / Period	What It Supports
Tempus Reports Second Quarter 2026 Results / Tempus AI	Company IR / earnings filing	Q2 2026	Latest operating results, guidance, products and financial supplement
TEM complete earnings-call transcript	Transcript	Q2 2026	Prepared remarks and all material Q&A exchanges
TEM regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
TEM valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
TEM historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
TEM historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
TEM historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Natera statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Guardant Health statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
SEC XBRL company facts — TEM	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics

Research context

• Company: Tempus AI, Inc.

• Ticker: TEM

• Exchange: Nasdaq

• Sector / Industry: Health Care / diagnostics and clinical data

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $77.80 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: No

• Primary operating period reviewed: Q2 2026

• Historical period reviewed: TTM, FY 2025, FY 2024; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q2 2026, complete material Q&A

• Latest post-earnings management commentary reviewed: No separate later management presentation incorporated

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

TEM — Tempus AI, Inc.

Company & Research Metadata

• Company: Tempus AI, Inc.

• Ticker: TEM

• Exchange: Nasdaq

• Sector / Industry: Health Care / diagnostics and clinical data

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $77.80 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: No

• Primary operating period reviewed: Q2 2026

• Historical period reviewed: TTM, FY 2025, FY 2024; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q2 2026, complete material Q&A

• Latest post-earnings management commentary reviewed: No separate later management presentation incorporated

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

What's Changed Since Previous Review

Current Review: 2026-10-28

Previous Review: 2026-10-21

Update Trigger: Competitor relevance and analyst-Q&A correction

Area	Previous View	Current View	Investment Impact
Competition	Preceding operating and comparable-company classifications	Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors	Corrects the competitive comparison; does not by itself re-underwrite the valuation
Analyst questions	Prior source-linked Q&A summaries	Complete questions and sentence-form management answers; all 8 existing rows retained	Improves readability while preserving the recorded exchange meaning
Valuation and scores	Approved operating/price snapshots, scenarios, scores and decisions	Preserved	No price refresh, rerank or change to valuation assumptions in this correction pass

Thesis: No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

Investment Snapshot

Metric	Current View
Price Snapshot	$77.80 — 2026-11-03 regular-session close, America/New_York
Rating / Zone Status	Avoid
Bear / Base / Bull Fair Value	$3.65 / $33.11 / $85.21
Scenario Probabilities	30% / 50% / 20%
Probability-Weighted Fair Value	$34.69
Probability-Weighted Expected Return	-55.4%
Bear-Case Return	-95.3%
Strong Buy Zone	≤ $4.02
Buy Zone	>$4.02–$27.75
Avoid Chasing Above	> $38.54
Quality Score / Tier	62.7 / Tier C
Opportunity Score / Rank	23.0 / #74 of 76
Risk Level	High
Tracking / Ownership	Primary Watchlist / Not Owned

Decision rationale: TEM is Avoid at $66.75, with -48.0% probability-weighted upside and -94.5% bear-case return. A differentiated clinical dataset can create a reinforcing relationship between testing and high-value research products. Confidence is 28/100 because the earnings conversion, competitive and capital assumptions below remain conditional.

Investment Thesis

A differentiated clinical dataset can create a reinforcing relationship between testing and high-value research products. Q2 revenue grew 22%, with data licensing up 36% and oncology testing volume up 31%. The debate is whether that growth becomes durable cash earnings after laboratory costs, compensation, acquisitions and financing. AI branding should not obscure reimbursement and healthcare-service economics.

What the Market May Be Mispricing

Debate	Research judgment
Diagnostic reimbursement and organic volume	A differentiated clinical dataset can create a reinforcing relationship between testing and high-value research products.
Data licensing durability and legal rights	Test reimbursement, collection rates, laboratory contribution, repeat ordering and licensing renewals drive returns.
Acquisition integration, cash burn and dilution	Q2 revenue was $382.5 million and adjusted EBITDA $8 million.

Business Overview

Tempus combines molecular diagnostics with clinical data, AI tools and data licensing for physicians and life-science companies. Testing creates clinical and molecular information that can support research and software products, subject to consent, privacy and data rights. Diagnostics and licensing have different margins, reimbursement and cash cycles. Acquisitions, including broader hereditary and residual-disease capabilities, expand scale while complicating organic comparisons.

Business Takeaway

Tempus combines molecular diagnostics with clinical data, AI tools and data licensing for physicians and life-science companies. Test reimbursement, collection rates, laboratory contribution, repeat ordering and licensing renewals drive returns.

Industry, TAM & Market Share

Precision medicine and residual-disease testing offer substantial opportunities, but clinical utility, reimbursement and physician adoption determine the reachable market. Established diagnostics companies and private clinical-data platforms compete. Large disease populations are not immediately monetizable test volumes.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Foundation Medicine — Roche	Direct: oncology molecular profiling and related clinical data	Product scope; no matched operating-scale series	Competes for specified tests and data contracts	Customer choice in the stated segment only
Guardant Health (GH)	Direct segment: liquid biopsy and oncology testing	Product scope; no matched operating-scale series	Compare assay, clinical use and reimbursement	Customer choice in the stated segment only
Natera (NTRA)	Direct segment: residual-disease/oncology monitoring	Product scope; no matched operating-scale series	Competes in overlapping oncology assays	Customer choice in the stated segment only

Industry Takeaway

Large disease populations are not immediately monetizable test volumes. The base case requires evidence of profitable adoption within that market.

Customer Economics

Test reimbursement, collection rates, laboratory contribution, repeat ordering and licensing renewals drive returns. Data contracts can improve margins but may be concentrated and uneven. Dataset breadth creates value only if information quality and lawful usage support repeat demand.

Customer-Economics Takeaway

The economic test is Acquisition integration, cash burn and dilution. Dataset breadth creates value only if information quality and lawful usage support repeat demand.

Competitive Landscape & Moat

Competitive Landscape

Compare a specific assay, clinical use or data product. Molecular testing companies are not interchangeable across screening, therapy selection and residual-disease monitoring.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Foundation Medicine — Roche	No consistent comparable series	Direct: oncology molecular profiling and related clinical data	Established genomic-testing and pharmaceutical relationships	Different data breadth and software/licensing mix	Competes for specified tests and data contracts
Guardant Health (GH)	No consistent comparable series	Direct segment: liquid biopsy and oncology testing	Blood-based oncology testing capabilities	Not every test or patient indication overlaps	Compare assay, clinical use and reimbursement
Natera (NTRA)	No consistent comparable series	Direct segment: residual-disease/oncology monitoring	Established molecular monitoring workflows	Other reproductive/organ-health products are outside this comparison	Competes in overlapping oncology assays

Moat Assessment

Integrated clinical and molecular data, physician relationships and workflow embedding create potential advantages. The moat remains partly dependent on acquisitions, data access and demonstrable customer outcomes.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Integrated clinical and molecular data, physician relationships and workflow embedding create potential advantages. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Financial Profile

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2024	693.4	30.38%	54.96%	-99.66%	-211.17	-30.45%	534.14	120	448.26	468.09
FY2025	1,272	83.41%	62.74%	-19.44%	-239.14	-18.80%	124.75	174	755	1,327
Q1 FY2026	$348.116	N/D	N/D	-24.3%	−$81.479 (derived: CFO - capex)	-23.4%	$52.706	0.179	$521.17	N/D
Q2 FY2026	$382.486	N/D	N/D	-19.8%	−$13.65 (derived: current YTD - prior YTD)	-3.6%	$54.121 (derived: current YTD - prior YTD)	0.182	$599.614	N/D
H1 FY2026	$730.602	N/D	N/D	-22.0%	−$95.129 (derived: CFO - capex)	-13.0%	$106.827	0.179	$599.614	N/D
Q3 FY2026	$411.537	N/D	N/D	-13.8%	−$0.122 (derived: current YTD - prior YTD)	-0.0%	$48.074 (derived: current YTD - prior YTD)	0.181	$590.479	N/D
9M FY2026	$1,142.139	N/D	N/D	-19.0%	−$95.251 (derived: CFO - capex)	-8.3%	$154.901	0.18	$590.479	N/D

Financial Takeaways

Q2 revenue was $382.5 million and adjusted EBITDA $8 million. TTM FCF remained negative $263 million, with SBC $186 million and substantial debt or convertible financing. Positive quarterly net income can include items that do not establish sustainable cash profitability. The model includes financing costs and dilution.

Financial direction: Mixed — assess the reported trend alongside dilution and the balance sheet.

Management & Capital Allocation

Management has built a differentiated platform but pursued an ambitious acquisition strategy. Governance, related-party exposure and the price paid for expansion deserve scrutiny. Monitor organic growth, reimbursement quality, cash burn and the common-share implications of convertibles and M&A.

Management Takeaway

Monitor organic growth, reimbursement quality, cash burn and the common-share implications of convertibles and M&A.

Valuation

Current Valuation

Metric	Value
Price Snapshot	$77.80 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$12.04B
Enterprise Value	$12.67B
Trailing P/E	n/a
Provider forward P/E	n/a
EV / Sales	8.85

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
TEM — Tempus AI, Inc.	Subject company	Public	n/a	8.85	diagnostics and clinical data; 3Y revenue-growth estimate 23.04%; operating margin -19.69%
Foundation Medicine	Direct operating competitor / substitute	Operating business of listed Roche	N/A	N/A	direct oncology testing and clinical-data competition; no compatible standalone public multiple used
NTRA — Natera	Direct selected oncology/MRD assays; other testing segments differ	Public	n/a	21.29	genetic testing and oncology monitoring; 3Y revenue-growth estimate 22.84%; operating margin -10.54%
GH — Guardant Health	Direct selected oncology/liquid-biopsy assays	Public	n/a	18.99	oncology testing and liquid biopsy; 3Y revenue-growth estimate 36.25%; operating margin -39.64%
Foundation Medicine — Roche	Direct: oncology molecular profiling and related clinical data	Operating product / listed parent	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes for specified tests and data contracts

Comparable takeaway: Compare a specific assay, clinical use or data product. Molecular testing companies are not interchangeable across screening, therapy selection and residual-disease monitoring. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR 15%; sustainable 2029 EPS $0.30 after compensation; 20× P/E; 18% discount rate; Reimbursement and financing pressure leave 2029 economic EPS at $0.30.	$3.65	30%	Execution, financing or competitive setbacks remain credible	-95.3%
Base	3Y revenue CAGR 30%; sustainable 2029 EPS $1.70 after compensation; 32× P/E; 18% discount rate; Diagnostics and data scale successfully, producing $1.70 of 2029 economic EPS.	$33.11	50%	Most likely operating trajectory, requiring measurable progress	-57.4%
Bull	3Y revenue CAGR 42%; sustainable 2029 EPS $3.50 after compensation; 40× P/E; 18% discount rate; Strong clinical adoption and high-margin data demand produce $3.50 of 2029 economic EPS.	$85.21	20%	Successful product conversion and operating leverage; not assured	+9.5%
Probability-Weighted	Sum of each scenario value × its probability	$34.69	100%	Judgmental scenario probabilities	-55.4%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: Diagnostic reimbursement and organic volume; Data licensing durability and legal rights; Acquisition integration, cash burn and dilution. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 28/100 / High. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Avoid at $66.75. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Analyst Questions

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Kallum Titchmarsh / Morgan Stanley	How does reimbursement timing affect assumptions for Personalis?	Management said reimbursement timing changes partner economics.	Confirm that this opportunity converts into profitable recurring demand.
Brad Bowers / Mizuho	How do the AstraZeneca contracts affect 2027 visibility?	Management said a large customer commitment supports 2027.	Confirm that this opportunity converts into profitable recurring demand.
Kyle Mikson / Canaccord	What is the reimbursement outlook for liquid-biopsy pricing?	Management said reimbursement upside exceeds prior assumptions.	Stress monetization if competition or mix reduces economic yield.
Matt Shea / Needham	What supports data-product demand?	Management said the pipeline and customer stickiness are improving.	Confirm that this opportunity converts into profitable recurring demand.
Mark Massaro / BTIG	How are Medicare reimbursement and test economics balanced against volume growth?	Management said profitable growth takes priority over uneconomic volume.	Confirm that this opportunity converts into profitable recurring demand.
Ricki Levitus / Guggenheim	How is GenomeNext's initial ramp progressing?	Management said the first month was ahead of expectations.	Confirm that this opportunity converts into profitable recurring demand.
Brendan Smith / TD Cowen	How should investors interpret the timing of data revenue?	Management said embedded partnerships differ from one-off file sales.	Treat the stated timetable as conditional on demonstrated execution.
Robert Bamberger / Baird	How does algorithm attachment affect testing adoption?	Management said attachment supports clinical adoption and test growth.	Confirm that this opportunity converts into profitable recurring demand.

Analyst-Q&A Takeaway

Reimbursement and data partnerships improve the opportunity, but prices, revenue timing and Personalis economics remain sensitive. Profitable test volume and cash conversion matter more than assay growth alone.

Thesis Monitoring

Driver	Current State	Positive Trigger / Catalyst	Negative Trigger / Falsifier	What It Changes
Diagnostic reimbursement and organic volume	A differentiated clinical dataset can create a reinforcing relationship between testing and high-value research products.	Revenue trajectory sustains approximately 30% annual growth on a comparable basis	Growth remains below the 15% bear assumption over a full operating cycle	Revenue outlook and scenario probabilities
Data licensing durability and legal rights	Test reimbursement, collection rates, laboratory contribution, repeat ordering and licensing renewals drive returns.	After-cost earnings progress toward the base implied net margin of 11.0%	Competition, credit losses or service costs make that margin trajectory unattainable	Margins, moat score and valuation multiple
Acquisition integration, cash burn and dilution	Q2 revenue was $382.5 million and adjusted EBITDA $8 million.	Financing and compensation remain consistent with 203.0M economic shares in the 2029 base case	Required capital or cumulative dilution materially exceeds the model without matching earnings	Financial score, confidence and downside value

Quality & Opportunity Scorecards

Quality Score

Component	Score	Weight	Weighted Contribution	Evidence
Business durability and economics	59	25%	14.8	Test reimbursement, collection rates, laboratory contribution, repeat ordering and licensing renewals drive returns.
Moat and competitive position	70	25%	17.5	Integrated clinical and molecular data, physician relationships and workflow embedding create potential advantages.
Growth runway and durability	89	20%	17.8	Precision medicine and residual-disease testing offer substantial opportunities, but clinical utility, reimbursement and physician adoption determine the reachable market.
Financial quality and balance sheet	38	15%	5.7	Q2 revenue was $382.5 million and adjusted EBITDA $8 million.
Management, governance and capital allocation	46	15%	6.9	Management has built a differentiated platform but pursued an ambitious acquisition strategy.
Quality Score	62.7	100%	62.7	Weighted score, independent of ownership and current price

• Quality Tier: C
• Speculative override: None

Opportunity Score

Component	Raw Input	Normalized Score	Weight	Weighted Contribution
Quality	62.7	62.7	30%	18.8
Probability-weighted upside	-55.4%	0.0	35%	0.0
Bear-case downside	-95.3%	0.0	20%	0.0
Risk / valuation confidence	28	28.0	15%	4.2
Opportunity Score		23.0	100%	23.0

• Opportunity Rank: #74 of 76
• Zone Status: Avoid

Portfolio Context

• Tracking tier: Primary Watchlist
• Owned: No
• Tracking source of truth: my_watchlist.md
• Portfolio source of truth: portfolio/holdings.md
• Scoring independence: Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

Investment Decision History

Timestamp	Price	Rating	Zone Status	Buy Zone	Strong Buy Zone	Avoid Chasing Above	Base FV	P/W FV	P/W Return	Quality	Opportunity / Rank	Change / Rationale
2026-10-21 (America/New_York)	$66.75	Avoid	Avoid	>$4.02–$27.75	≤ $4.02	> $38.54	$33.11	$34.69	-48.0%	62.7	23.0 / #68	Initial missing-file analysis; common-universe ranking; independent scenario assumptions

---

Material Sources

Source	Type	Date / Period	What It Supports
Tempus Reports Second Quarter 2026 Results / Tempus AI	Company IR / earnings filing	Q2 2026	Latest operating results, guidance, products and financial supplement
TEM complete earnings-call transcript	Transcript	Q2 2026	Prepared remarks and all material Q&A exchanges
TEM regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
TEM valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
TEM historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
TEM historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
TEM historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Natera statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Guardant Health statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
SEC XBRL company facts — TEM	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics